TY - JOUR
T1 - Screening for asymptomatic coronary artery disease can reduce cardiovascular mortality and morbidity in type 2 diabetic patients
AU - Gazzaruso, Carmine
AU - Coppola, Adriana
AU - Montalcini, Tiziana
AU - Valenti, Cinzia
AU - Pelissero, Gabriele
AU - Solerte, Sebastiano Bruno
AU - Salvucci, Fabrizio
AU - Gallotti, Pietro
AU - Pujia, Arturo
AU - Garzaniti, Adriana
AU - Giustina, Andrea
PY - 2012/6
Y1 - 2012/6
N2 - The impact of the screening for asymptomatic coronary artery disease (CAD) on the cardiovascular prognosis in diabetes is controversial. The aim of the study was to investigate whether screening for asymptomatic CAD can have an impact on cardiovascular morbidity and mortality in diabetes. In this nonrandomized longitudinal study, 1,189 consecutive type 2 diabetic patients without a history of CAD were evaluated. They were subdivided into two groups according to whether they were screened (screening group, n = 921) or not (no-screening group, n = 268) for asymptomatic CAD. Among the screened patients, 386 had angiographically proven CAD (CAD group) and 535 did not have silent CAD (no-CAD group). During a mean follow-up period of 4. 3 ± 1. 9 years, 130 patients experienced major adverse cardiac events (MACE). The incidence of MACE was significantly greater in the no-screening than in the screening group (22. 0 vs. 7. 7%; p = 0. 001). The Kaplan-Meier method showed that: (1) the screening was associated with a lower rate of MACE (log-rank test, 3-95; p = 0. 047); (2) the no-screening group had a risk profile similar to that of CAD group (log-rank test, 2. 02; p = 0. 154); and (3) cardiovascular prognosis was significantly better in no-CAD than in no-screening group (log-rank test, 4. 27; p = 0. 039). Multivariate Cox regression analysis showed that screening for CAD (HR 0. 2; 95% CI 0. 2-0. 3; p = 0. 000) was significantly protective against the occurrence of MACE. Our data suggest that screening for asymptomatic CAD can significantly reduce cardiovascular morbidity and mortality in type 2 diabetic patients. This may be due to specific diagnostic and therapeutic interventions in diabetic patients with proven CAD at screening.
AB - The impact of the screening for asymptomatic coronary artery disease (CAD) on the cardiovascular prognosis in diabetes is controversial. The aim of the study was to investigate whether screening for asymptomatic CAD can have an impact on cardiovascular morbidity and mortality in diabetes. In this nonrandomized longitudinal study, 1,189 consecutive type 2 diabetic patients without a history of CAD were evaluated. They were subdivided into two groups according to whether they were screened (screening group, n = 921) or not (no-screening group, n = 268) for asymptomatic CAD. Among the screened patients, 386 had angiographically proven CAD (CAD group) and 535 did not have silent CAD (no-CAD group). During a mean follow-up period of 4. 3 ± 1. 9 years, 130 patients experienced major adverse cardiac events (MACE). The incidence of MACE was significantly greater in the no-screening than in the screening group (22. 0 vs. 7. 7%; p = 0. 001). The Kaplan-Meier method showed that: (1) the screening was associated with a lower rate of MACE (log-rank test, 3-95; p = 0. 047); (2) the no-screening group had a risk profile similar to that of CAD group (log-rank test, 2. 02; p = 0. 154); and (3) cardiovascular prognosis was significantly better in no-CAD than in no-screening group (log-rank test, 4. 27; p = 0. 039). Multivariate Cox regression analysis showed that screening for CAD (HR 0. 2; 95% CI 0. 2-0. 3; p = 0. 000) was significantly protective against the occurrence of MACE. Our data suggest that screening for asymptomatic CAD can significantly reduce cardiovascular morbidity and mortality in type 2 diabetic patients. This may be due to specific diagnostic and therapeutic interventions in diabetic patients with proven CAD at screening.
KW - Cardiovascular prognosis
KW - Diabetes
KW - Screening
KW - Silent coronary artery disease
UR - http://www.scopus.com/inward/record.url?scp=84862185592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862185592&partnerID=8YFLogxK
U2 - 10.1007/s11739-011-0527-5
DO - 10.1007/s11739-011-0527-5
M3 - Article
C2 - 21298361
AN - SCOPUS:84862185592
VL - 7
SP - 257
EP - 266
JO - Internal and Emergency Medicine
JF - Internal and Emergency Medicine
SN - 1828-0447
IS - 3
ER -